Amgen's Two-Brand Strategy for Biosimilars for Adalimumab

European Medicines Agency (EMA) approved Amgen’s Amgevita and Solymbic both of which are biosimilars for adalimumab. Two biosimilars are identical molecules with same indications except for the additional indication for pediatric juvenile idiopathic arthritis (JIA) for Amgevita. A two-brand strategy is not uncommon in Europe. Celltrion, a Korean pharmaceutical company, utilized the two-brand strategy with Inflectra and Remsima which are biosimilars for remicade for marketing purposes to cater to local needs.

Click here for Source

#Amgen #biosimilar #adalimumab #amgevita #solymbic #twobrand